AI startup raises $62M for robotic endovascular interventions

Remedy Robotics, a San Francisco-based medtech company, has raised $62 million to fund the continued development of artificial intelligence (AI)-enabled robotic systems for cardiovascular care. This new round of financing is expected to go toward clinical research, deploying prototypes and working to secure U.S. Food and Drug Administration approvals. 

DCVC led the funding round. Additional investors included UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent capital and KdT Ventures.

Remedy’s flagship offering is the N1 System, an AI-powered robotic platform and software suite that can be used before and during various endovascular procedures. The company built this technology to improve patient access to potentially lifesaving interventions. The N1 System is still under development and has not been approved for sale or clinical use anywhere in the world. A planned pivotal trial is already on the way, and these funds will go director toward the completion of that analysis. 

Subscribe to Cardiovascular Business News

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals,” David Bell, MBBS, CEO and co-founder of Remedy Robotics, said in a statement. “For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common. This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography.”

“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” added Jake Sganga, chief technology officer and co-founder of Remedy Robotics. “We are particularly excited to deepen our partnership with the University of California (UC), having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News